{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T17:06:21Z","timestamp":1781888781663,"version":"3.54.5"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R01EY030283"],"award-info":[{"award-number":["R01EY030283"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Stevens Johnsons syndrome (SJS) is a mucocutaneous disorder caused by an autoimmune response most commonly to medications. Unless it is properly managed in the acute setting, this entity can affect the ocular surface causing chronic cicatrizing conjunctivitis with limbal stem cell deficiency and lid anomalies which ultimately result in corneal opacities that may limit patients' visual acuity. When this stage is reached, some patients might need to undergo some form of corneal and\/or limbal stem cell transplantation that exposes an already sensitized immune system to a new alloantigen. While the innate immunity plays a role in corneal graft survival, adaptive immune responses play a major part in corneal graft rejection and failure, namely through CD4+ T cell lymphocytes. Hence, the management of the immune response to surgical transplant procedures in SJS patients, involves a dual approach that modulates the inflammatory response to a new alloantigen in the context of an autoimmune sensitized patient. This review will explore and discuss current perspectives and future directions in the field of ocular immunology on how to manage SJS immune responses to ocular surgical procedures, reviewing systemic and local immunosuppressive therapies and protocols to adequately manage this debilitating condition.<\/jats:p>","DOI":"10.3389\/fmed.2021.656998","type":"journal-article","created":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T06:11:03Z","timestamp":1621577463000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Understanding Immune Responses to Surgical Transplant Procedures in Stevens Johnsons Syndrome Patients"],"prefix":"10.3389","volume":"8","author":[{"given":"Matias","family":"Soifer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem M.","family":"Mousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor L.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-Study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/archderm.126.1.43","article-title":"The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients","volume":"126","author":"Chan","year":"1990","journal-title":"Arch Dermatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/0895-4356(96)00035-2","article-title":"Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990\u20131992): structure and results of a population-based registry","volume":"49","author":"Rzany","year":"1996","journal-title":"J Clin Epidemiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/pds.3937","article-title":"Incidence, causative factors and mortality rates of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: data from the REACT registry: incidence of SJS and TEN in northern Italy","volume":"25","author":"Diphoorn","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jtos.2015.10.002","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis \u2013 a comprehensive review and guide to therapy. I. systemic disease","volume":"14","author":"Kohanim","year":"2016","journal-title":"Ocul Surf."},{"key":"B6","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1046\/j.1365-2249.2000.01119.x","article-title":"Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors","volume":"119","author":"Le Cleach","year":"2000","journal-title":"Clin Exp Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1001\/archderm.130.5.605","article-title":"Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis","volume":"130","author":"Paquet","year":"1994","journal-title":"Arch Dermatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s12016-017-8654-z","article-title":"Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"54","author":"Lerch","year":"2018","journal-title":"Clinic Rev Allerg Immunol."},{"key":"B9","first-page":"157","article-title":"Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume-title":"Arch Dermatol.","author":"Gueudry","year":"2009"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1097\/ICO.0b013e31823d02a8","article-title":"Indications and outcomes of amniotic membrane transplantation in the management of acute Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: a case\u2013control study","volume":"31","author":"Hsu","year":"2012","journal-title":"Cornea."},{"key":"B11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ajo.2018.01.028","article-title":"Chronic ocular sequelae of Stevens-Johnson syndrome in children: long-term impact of appropriate therapy on natural history of disease","volume":"189","author":"Basu","year":"2018","journal-title":"Am J Ophthalmol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1097\/00003226-200009000-00008","article-title":"Twenty-five\u2013year panorama of corneal immunology: emerging concepts in the immunopathogenesis of microbial keratitis, peripheral ulcerative keratitis, and corneal transplant rejection","volume":"19","author":"Dana","year":"2000","journal-title":"Cornea."},{"key":"B13","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1097\/01.tp.0000185197.37824.35","article-title":"How effective is penetrating corneal transplantation? Factors influencing long-term outcome in multivariate analysis","volume":"81","author":"Williams","year":"2006","journal-title":"Transplantation."},{"key":"B14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.4103\/2008-322X.200156","article-title":"Systemic immunomodulatory strategies in high-risk corneal transplantation","volume":"12","author":"Abud","year":"2017","journal-title":"J Ophthalmic Vis Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"535","DOI":"10.4049\/jimmunol.0903180","article-title":"Cutting edge: lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation","volume":"184","author":"Dietrich","year":"2010","journal-title":"J Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.4049\/jimmunol.167.5.2979","article-title":"Early chemokine cascades in murine cardiac grafts regulate T cell recruitment and progression of acute allograft rejection","volume":"167","author":"Morita","year":"2001","journal-title":"J Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1111\/ajt.12228","article-title":"Role of T cell recruitment and chemokine-regulated intra-graft T cell motility patterns in corneal allograft rejection","volume":"13","author":"Tan","year":"2013","journal-title":"Am J Transplant."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0161-6420(02)00960-0","article-title":"Long-term outcome of keratolimbal allograft with or without penetrating keratoplasty for total limbal stem cell deficiency","volume":"109","author":"Solomon","year":"2002","journal-title":"Ophthalmology."},{"key":"B19","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1136\/bjo.83.4.414","article-title":"Allo-limbal transplantation in patients with limbal stem cell deficiency","volume":"83","author":"Dua","year":"1999","journal-title":"Br J Ophthalmol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1097\/ICO.0b013e31823f8b0c","article-title":"Systemic immunosuppression in ocular surface stem cell transplantation: results of a 10-year experience","volume":"31","author":"Holland","year":"2012","journal-title":"Cornea."},{"key":"B21","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1097\/ICO.0b013e318201467c","article-title":"The cincinnati procedure: technique and outcomes of combined living-related conjunctival limbal allografts and keratolimbal allografts in severe ocular surface failure","volume":"30","author":"Biber","year":"2011","journal-title":"Cornea."},{"key":"B22","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","article-title":"Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel","volume":"130","author":"Jabs","year":"2000","journal-title":"Am J Ophthalmol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.jtos.2013.02.003","article-title":"Current medical treatment of ocular mucous membrane pemphigoid","volume":"11","author":"Sobolewska","year":"2013","journal-title":"Ocul Surf."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1016\/j.ophtha.2005.02.020","article-title":"Mycophenolate mofetil therapy for inflammatory eye disease","volume":"112","author":"Thorne","year":"2005","journal-title":"Ophthalmology."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1038\/eye.2008.402","article-title":"Mycophenolate mofetil (MMF) following penetrating high-risk keratoplasty: long-term results of a prospective, randomised, multicentre study","volume":"23","author":"Birnbaum","year":"2009","journal-title":"Eye."},{"key":"B26","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/j.1432-2277.2005.00126.x","article-title":"Systemic mycophenolate mofetil avoids immune reactions in penetrating high-risk keratoplasty: preliminary results of an ongoing prospectively randomized multicentre study*","volume":"18","author":"Reinhard","year":"2005","journal-title":"Transplant Int."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1093\/ndt\/15.12.1916","article-title":"Clinical and mechanistic differences between FK506 (tacrolimus) and cyclosporin A","volume":"15","author":"Almawi","year":"2000","journal-title":"Nephrol Dial Transplant."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0041-1345(98)00226-7","article-title":"Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus","volume":"30","author":"Friemann","year":"1998","journal-title":"Transplant Proc."},{"key":"B29","article-title":"Minor salivary gland transplantation for severe dry eye disease due to cicatrising conjunctivitis: multicentre long-term outcomes of a modified technique","volume-title":"Br J Ophthalmol.","author":"Vazirani","year":"2020"},{"key":"B30","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.ajo.2020.07.006","article-title":"Lid-related keratopathy in Stevens-Johnson syndrome: natural course and impact of therapeutic interventions in children and adults","volume":"219","author":"Shanbhag","year":"2020","journal-title":"Am J Ophthalmol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e605","DOI":"10.1111\/aos.12710","article-title":"Autologous serum and plasma rich in growth factors in ophthalmology: preclinical and clinical studies","volume":"93","author":"Anitua","year":"2015","journal-title":"Acta Ophthalmol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1126\/science.1079490","article-title":"Control of regulatory T cell development by the transcription factor Foxp3","volume":"299","author":"Hori","year":"2003","journal-title":"Science."},{"key":"B33","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","article-title":"Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases","volume":"155","author":"Sakaguchi","year":"1995","journal-title":"J Immunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nri2343","article-title":"How regulatory T cells work","volume":"8","author":"Vignali","year":"2008","journal-title":"Nat Rev Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1084\/jem.20012097","article-title":"Identification of regulatory T Cells in tolerated allografts","volume":"195","author":"Graca","year":"2002","journal-title":"J Exp Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.immuni.2006.08.003","article-title":"From vanilla to 28 flavors: multiple varieties of T regulatory cells","volume":"25","author":"Shevach","year":"2006","journal-title":"Immunity."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1182\/blood-2004-03-0859","article-title":"Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells","volume":"104","author":"Grossman","year":"2004","journal-title":"Blood."},{"key":"B38","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1365-2567.2006.02362.x","article-title":"Cytotoxic T lymphocyte antigen-4-dependent down-modulation of costimulatory molecules on dendritic cells in CD4+ CD25+ regulatory T-cell-mediated suppression","volume":"118","author":"Oderup","year":"2006","journal-title":"Immunology."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1038\/ni1536","article-title":"CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells","volume":"8","author":"Pandiyan","year":"2007","journal-title":"Nat Immunol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1172\/JCI59411","article-title":"Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation","volume":"122","author":"Bohne","year":"2012","journal-title":"J Clin Invest."},{"key":"B41","first-page":"283","article-title":"Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants","volume-title":"JAMA.","author":"Feng","year":"2012"},{"key":"B42","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/hep.28459","article-title":"A pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation","volume":"64","author":"Todo","year":"2016","journal-title":"Hepatology."},{"key":"B43","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.3389\/fimmu.2018.03104","article-title":"BET bromodomain inhibitors which permit treg function enable a combinatorial strategy to suppress GVHD in pre-clinical allogeneic HSCT","volume":"9","author":"Copsel","year":"2018","journal-title":"Front Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/j.bbmt.2018.04.026","article-title":"Very low numbers of CD4+ FoxP3+ tregs expanded in donors via TL1A-Ig and low-dose IL-2 exhibit a distinct activation\/functional profile and suppress GVHD in a preclinical model","volume":"24","author":"Copsel","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e121717","DOI":"10.1172\/jci.insight.121717","article-title":"Superior immune reconstitution using Treg-expanded donor cells versus PTCy treatment in preclinical HSCT models","volume":"3","author":"Wolf","year":"2018","journal-title":"JCI Insight."},{"key":"B46","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.bbmt.2017.02.013","article-title":"Marked in vivo donor regulatory T cell expansion via interleukin-2 and TL1A-Ig stimulation ameliorates graft-versus-host disease but preserves graft-versus-leukemia in recipients after hematopoietic stem cell transplantation","volume":"23","author":"Wolf","year":"2017","journal-title":"Biol Blood Marrow Transplant."},{"key":"B47","doi-asserted-by":"publisher","first-page":"14532","DOI":"10.1073\/pnas.1212264109","article-title":"Selective inhibition of CD4+ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors","volume":"109","author":"Bandukwala","year":"2012","journal-title":"Proc Natl Acad Sci."},{"key":"B48","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.cell.2013.07.013","article-title":"BET bromodomains mediate transcriptional pause release in heart failure","volume":"154","author":"Anand","year":"2013","journal-title":"Cell."},{"key":"B49","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/biomedicines6010016","article-title":"BET family protein BRD4: an emerging actor in NF\u03baB signaling in inflammation and cancer","volume":"6","author":"Hajmirza","year":"2018","journal-title":"Biomedicines."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.3892\/mmr.2020.10927","article-title":"General mechanism of JQ1 in inhibiting various types of cancer","volume":"21","author":"Jiang","year":"2020","journal-title":"Mol Med Rep."},{"key":"B51","doi-asserted-by":"publisher","first-page":"e000744","DOI":"10.1136\/rmdopen-2018-000744","article-title":"Bromodomain protein inhibition: a novel therapeutic strategy in rheumatic diseases","volume":"4","author":"Klein","year":"2018","journal-title":"RMD Open."},{"key":"B52","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.canlet.2017.02.021","article-title":"Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer","volume":"394","author":"Leal","year":"2017","journal-title":"Cancer Lett."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.656998\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T00:17:44Z","timestamp":1699057064000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.656998\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,21]]},"references-count":52,"alternative-id":["10.3389\/fmed.2021.656998"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.656998","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,21]]},"article-number":"656998"}}